Is this why Guardion Health Sciences, Inc. (GHSI) shares took the aerial route last night?

GILD Stock
GILD Stock

Guardion Health Sciences, Inc. (NASDAQ: GHSI) shares rose 26.25% to $0.4689 in the post-‎market hours Wednesday. There’s no news specific to stock, so investors might want to take ‎this as a bullish sign. , The only information that might have influenced this rise was on ‎December 16, 2020, when the company revealed that it had made progress in developing a ‎new vision support/energy drink, Epiq-V, which has been under development for the United ‎States and international markets.‎

Get the hottest ‎stocks to trade every day before the market opens 100% ‎free. Click here ‎now. 

‎Lumega-Z is marketed mainly to the children market as an eye health and support product. ‎At the same time, Epiq-V is being developed for an adult market as a visual attention and ‎energy drink that helps support video gaming and other close-up device-viewing demands of ‎the teens market. The initial round of testing has been completed, and the final round is ‎currently underway and is expected to be completed by the end of the first quarter of 2021. ‎For the Asian market, specifically China, Epiq-V has already secured trademark protection ‎‎(using Chinese characters) for its brand name. A trademark application has been submitted ‎for approval in the United States.‎

Top 5 EV Tech Stocks to Buy for 2023

The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".

Click Here to Download the FREE Report.


Read More

The company’s interim President and Chief Executive Officer, David Evans, Ph.D., ‎said, “We have long emphasized the importance of accessing new markets with our ‎unique formulation capabilities, and we built up our Asia presence during 2020.” ‎With the development and eventual distribution of Epiq-V, we hope to expand our ‎presence in Asia by providing a product line that is designed to support overall ‎ocular health and attention.”‎


Please enter your comment!
Please enter your name here